-
1.发明授权公开(公告)号：US09452139B2
公开(公告)日：2016-09-27
申请号：US14202262
申请日：2014-03-10
IPC分类号： A61K9/16 , A61K45/06 , A61K47/02 , A61K9/00 , A61K47/24 , A61K9/14 , A61K31/40 , A61K31/4704 , A61K31/58
CPC分类号： A61K31/58 , A61K9/0075 , A61K9/145 , A61K9/1611 , A61K9/1617 , A61K9/1682 , A61K31/40 , A61K31/4704 , A61K45/06 , A61K47/02 , A61K47/24 , Y10S514/826 , A61K2300/00
摘要： Embodiments of the present invention provide a dry powder composition comprising porous carrier particles associated with one, two, three or more micronized drugs or APIs wherein an ordered mixture between the micronized drug or drugs and the carrier particle results, such that the micronized drug or drugs adhere strongly to the carrier particles forming a stable ordered mixture of respirable agglomerates. Embodiments of the present invention further comprise a spray-drying process to create the respirable agglomerates. Embodiments of the present invention further relate to the use of the dry powder formulation comprising respirable agglomerates for the treatment of a patient having a disease or condition which is treatable thereby.
摘要翻译： 本发明的实施方案提供一种干粉组合物，其包含与一种，两种，三种或更多种微粉化药物或API相关联的多孔载体颗粒，其中微粉化药物或载体颗粒之间的有序混合物导致微粉化药物或药物 强烈地粘附到形成可呼吸团聚体的稳定有序混合物的载体颗粒。 本发明的实施方案还包括喷雾干燥方法以产生可呼吸团聚体。 本发明的实施方案还涉及包含可吸入附聚物的干粉制剂用于治疗具有可治疗疾病或病症的患者的用途。
-
公开(公告)号：US09439862B2
公开(公告)日：2016-09-13
申请号：US14243639
申请日：2014-04-02
IPC分类号： A61K9/14 , A61K9/16 , A61K9/00 , A61K47/24 , A61K31/465 , A61K31/496 , A61K31/58 , A61K31/7036 , A61K31/7048 , A61K38/29 , A61K45/06 , A61K47/02 , A61K9/10 , A61M15/00
CPC分类号： A61K9/1617 , A61K9/0075 , A61K9/008 , A61K9/0082 , A61K9/10 , A61K9/14 , A61K9/1611 , A61K9/1694 , A61K31/465 , A61K31/496 , A61K31/58 , A61K31/7036 , A61K31/7048 , A61K38/29 , A61K45/06 , A61K47/02 , A61K47/24 , A61M15/0065 , A61M2205/3306
摘要： Phospholipid based powders for drug delivery applications are disclosed. The powders comprise a polyvalent cation in an amount effective to increase the gel-to-liquid crystal transition temperature of the particle compared to particles without the polyvalent cation. The powders are hollow and porous and are preferably administered via inhalation.
-
公开(公告)号：US20140212504A1
公开(公告)日：2014-07-31
申请号：US14243639
申请日：2014-04-02
IPC分类号： A61K9/16 , A61K31/496 , A61K31/7048 , A61K38/29 , A61K45/06 , A61K31/58 , A61K31/465 , A61K31/7036 , A61K9/00
CPC分类号： A61K9/1617 , A61K9/0075 , A61K9/008 , A61K9/0082 , A61K9/10 , A61K9/14 , A61K9/1611 , A61K9/1694 , A61K31/465 , A61K31/496 , A61K31/58 , A61K31/7036 , A61K31/7048 , A61K38/29 , A61K45/06 , A61K47/02 , A61K47/24 , A61M15/0065 , A61M2205/3306
摘要： Phospholipid based powders for drug delivery applications are disclosed. The powders comprise a polyvalent cation in an amount effective to increase the gel-to-liquid crystal transition temperature of the particle compared to particles without the polyvalent cation. The powders are hollow and porous and are preferably administered via inhalation.
摘要翻译： 公开了用于药物递送应用的基于磷脂的粉末。 与没有多价阳离子的颗粒相比，粉末包含有效增加颗粒的凝胶 - 液晶的转变温度的多价阳离子。 粉末是中空的和多孔的，并且优选通过吸入给药。
-
公开(公告)号：US08664187B2
公开(公告)日：2014-03-04
申请号：US13404359
申请日：2012-02-24
申请人： Peter Challoner , Carlos Rodriguez , Emil Samara , Thomas E Tarara , John D Lord
发明人： Peter Challoner , Carlos Rodriguez , Emil Samara , Thomas E Tarara , John D Lord
IPC分类号： A61K31/70
CPC分类号： A61K9/0075 , A61K31/70
摘要： The present invention provides methods for the treatment of an endobronchial infection in a patient by administering to the endobronchial system of the patient a dry powder aerosol composition comprising from 90 to 130 mg of an aminoglycoside antibiotic one to three times a day for a first treatment period of 20 to 36 days.
摘要翻译： 本发明提供了通过向患者的支气管系统施用干粉气溶胶组合物来治疗患者内支气管感染的方法，所述干粉气溶胶组合物包含90至130mg的氨基糖苷类抗生素，每天一至三次，用于第一治疗期 为20至36天。
-
5.发明申请STABLE METAL ION-LIPID POWDERED PHARMACEUTICAL COMPOSITIONS FOR DRUG DELIVERY 有权稳定的金属离子粉末药物组合物用于药物递送公开(公告)号：US20130095153A1
公开(公告)日：2013-04-18
申请号：US13707563
申请日：2012-12-06
IPC分类号： A61K47/24
CPC分类号： A61K9/1617 , A61K9/0075 , A61K9/008 , A61K9/0082 , A61K9/10 , A61K9/14 , A61K9/1611 , A61K9/1694 , A61K31/465 , A61K31/496 , A61K31/58 , A61K31/7036 , A61K31/7048 , A61K38/29 , A61K45/06 , A61K47/02 , A61K47/24 , A61M15/0065 , A61M2205/3306
摘要： A microparticle for drug delivery comprises an active agent and an excipient, the excipient comprising a metal ion-lipid complex. The metal ion is chosen from the group consisting of lanthanide metals, actinide metals, group IIa and IIIb metals, transition metals or mixtures thereof. The lipid comprises a phospholipid. The complex results in a glass transition temperature increase of the microparticle.
摘要翻译： 用于药物递送的微粒包括活性剂和赋形剂，所述赋形剂包含金属离子 - 脂质复合物。 金属离子选自镧系金属，锕系金属，IIa族和IIIb族金属，过渡金属或其混合物。 脂质包含磷脂。 复合物导致微粒的玻璃化转变温度升高。
-
公开(公告)号：US20120148641A1
公开(公告)日：2012-06-14
申请号：US13404359
申请日：2012-02-24
IPC分类号： A61K9/00 , A61M15/00 , A61K31/7036
CPC分类号： A61K9/0075 , A61K31/70
摘要： The present invention provides methods for the treatment of an endobronchial infection in a patient by administering to the endobronchial system of the patient a dry powder aerosol composition comprising from 90 to 130 mg of an aminoglycoside antibiotic one to three times a day for a first treatment period of 20 to 36 days.
摘要翻译： 本发明提供了通过向患者的支气管系统施用干粉气溶胶组合物来治疗患者内支气管感染的方法，所述干粉气溶胶组合物包含90至130mg的氨基糖苷类抗生素，每天一至三次，用于第一治疗期 为20至36天。
-
公开(公告)号：US08168223B1
公开(公告)日：2012-05-01
申请号：US09886296
申请日：2001-06-21
CPC分类号： A61K9/008 , A61K9/0073 , A61K9/0075 , A61K9/0078 , A61K9/1611 , A61K9/1617 , A61K9/1635 , A61K9/1641 , A61K9/1652 , A61K9/1694 , A61K31/685 , Y02A50/41 , Y02A50/466 , Y02A50/472 , Y10S514/937 , Y10S977/904 , Y10S977/906 , Y10S977/926
摘要： Engineered particles are provided may be used for the delivery of a bioactive agent to the respiratory tract of a patient. The particles may be used in the form of dry powders or in the form of stabilized dispersions comprising a nonaqueous continuous phase. In particularly preferred embodiments the particles may be used in conjunction with an inhalation device such as a dry powder inhaler, metered dose inhaler or a nebulizer.
摘要翻译： 提供的工程颗粒可用于将生物活性剂递送到患者的呼吸道。 颗粒可以以干粉形式或以包含非水连续相的稳定分散体的形式使用。 在特别优选的实施方案中，颗粒可以与吸入装置如干粉吸入器，计量剂量吸入器或喷雾器结合使用。
-
公开(公告)号：US07790145B2
公开(公告)日：2010-09-07
申请号：US12012827
申请日：2008-02-05
IPC分类号： A61K9/00 , A61K9/10 , A61K9/12 , A61K9/14 , A61K38/00 , A61K38/02 , A61K47/42 , A61K31/56 , A61K31/565 , A61K31/567 , A61K31/568 , A61K31/569 , A61K31/57 , A61K31/573 , A61K31/575
CPC分类号： A61K9/008 , A61K9/0073 , A61K9/0075 , A61K9/0078 , A61K9/1611 , A61K9/1617 , A61K9/1635 , A61K9/1641 , A61K9/1652 , A61K9/1694 , A61K31/685 , Y10S514/937 , Y10S977/904 , Y10S977/906 , Y10S977/926
摘要： A respiratory dispersion is provided for the pulmonary delivery of at least two bioactive agents. The dispersion comprises a propellant suspension medium having dispersed therein a plurality of perforated microstructures, wherein the two bioactive agents are incorporated into individual perforated microstructures.
摘要翻译： 为肺部递送至少两种生物活性剂提供呼吸分散体。 分散体包括其中分散有多个穿孔微结构的推进剂悬浮介质，其中两种生物活性剂并入单独的穿孔微结构中。
-
公开(公告)号：US20080214481A1
公开(公告)日：2008-09-04
申请号：US11570584
申请日：2005-06-20
IPC分类号： A61K31/7036 , A61P31/04
CPC分类号： A61K9/0075 , A61K31/70
摘要： The present invention provides methods for the treatment of an endobronchial infection in a patient by administering to the endobronchial system of the patient a dry powder aerosol composition comprising from 90 to 130 mg of an aminoglycoside antibiotic one to three times a day for a first treatment period of 20 to 36 days.
摘要翻译： 本发明提供了通过向患者的支气管系统施用干粉气溶胶组合物来治疗患者内支气管感染的方法，所述干粉气溶胶组合物包含90至130mg的氨基糖苷类抗生素，每天一至三次，用于第一治疗期 为20至36天。
-
10.发明授权Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement 失效含有磷脂的稳定气体乳液用于超声对比度增强公开(公告)号：US07141235B2
公开(公告)日：2006-11-28
申请号：US09941395
申请日：2001-08-28
申请人： Leo A. Trevino , Ernest George Schutt , David H. Klein , Thomas E. Tarara , Jeffry G. Weers , Alexey Kabalnov
发明人： Leo A. Trevino , Ernest George Schutt , David H. Klein , Thomas E. Tarara , Jeffry G. Weers , Alexey Kabalnov
IPC分类号： A61B8/00
CPC分类号： A61K49/223 , A61K49/227
摘要： A gas emulsion forming composition comprising a dry, hollow, particulate, approximately microspherical material permeated with a gas or gas mixture, which upon dissolution in aqueous liquid forms a gas emulsion comprising a plurality of bubbles surrounded by a layer of at least a first and a second surfactant, wherein the first surfactant consists essentially of a phospholipid or mixture of phospholipids having at least one acyl chain which comprises at least 10 carbon atoms, and comprising at least about 5% w/w of total surfactant, and wherein the second surfactant may or may not be a phospholipid and is more water soluble than the first surfactant; kits for preparing such microbubbles; and methods for using such microbubbles as contrast agents.
摘要翻译： 一种气体乳液形成组合物，其包含渗透有气体或气体混合物的干燥，中空，微粒，近似微球的材料，其在溶解在水性液体中时形成气体乳液，所述气体乳液包含多个气泡，所述泡沫被至少第一和第 第二表面活性剂，其中第一表面活性剂基本上由磷脂或具有至少一个包含至少10个碳原子的酰基链，并且包含至少约5％w / w的总表面活性剂的磷脂的混合物组成，并且其中第二表面活性剂可以 或者可能不是磷脂并且比第一表面活性剂更可溶于水; 用于制备这种微泡的试剂盒; 以及使用这种微泡作为造影剂的方法。
-
-
-
-
-
-
-
-
-
搜索结果
48 条记录 (耗时 0.051 秒)